-->

KMWorld 2024 Is Nov. 18-21 in Washington, DC. Register now for $100 off!

Ontotext offers an AI-powered platform that speeds the process of discovering pharmaceutical candidates

Ontotext, a provider of enterprise knowledge graph (EKG) technology and semantic database engines, is releasing Target Discovery, an AI-powered platform that speeds the process of discovering new, safe, and efficient drug candidates.

Target Discovery empowers pharmaceutical companies, biotech startups, and healthcare enterprises by combining knowledge from all relevant sources, including public and proprietary data, with AI-derived data from scientific publications, patents, and clinical trials.

According to the company, with Target Discovery, scientists and researchers, translational biology professionals, and bioinformaticians can bring together all the knowledge about biomedical entities, such as genes, proteins, and compounds into a centralized knowledge graph.

The system then democratizes insight discovery through search tools and data visualization and provides transparent analytics to aid data-driven decision making. Ontotext’s Target Discovery helps biomedical experts without any technical skills utilize powerful AI-based analytics for both target identification and selection with visibility over the algorithms, according to the vendor.

Specific benefits of Target Discovery include:

  • Generating AI-derived insights from scientific literature, patents, and clinical trials
  • Providing advanced and customizable analytics for target selection
  • Achieving impactful innovation through novel hypothesis generation and evaluation
  • Realizing transparent insight provenance and evidence

“Developing new treatments requires a complex understanding of disease mechanisms and the ability to identify the relationships between molecular and genetic factors in the context of a specific disease,” said Todor Primov, head of life sciences product and solutions at Ontotext. “However, this knowledge resides across multiple disparate sources and consists of different modalities which makes building a holistic view for a specific disease challenging. Leveraging Target Discovery’s built in knowledge graph technology, organizations can significantly lower the cost of bringing new drugs to market and shorten the time for novel insight discovery from integrated data.”

For more information about this news, visit www.ontotext.com.

KMWorld Covers
Free
for qualified subscribers
Subscribe Now Current Issue Past Issues